Steppogenin
(Synonyms: 草大戟素) 目录号 : GC69956Steppogenin 是一种有效的 HIF-1α 和 DLL4 的抑制剂,其 IC50 值分别为 0.56 和 8.46 μM。Steppogenin 可用于血管生成疾病的研究,如实体瘤。
Cas No.:56486-94-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 0.56 ± 0.043 μM (HIF-1α), 8.46 ± 1.08 μM (DLL4)[1]
Steppogenin is a potent inhibitor of HIF-1α and DLL4, with IC50 values of 0.56 and 8.46 μM, respectively. Steppogenin can be sued for the research of angiogenic diseases, such as those involving solid tumors[1].
Steppogenin (0-10 μM, 24 h) 以剂量依赖性方式抑制 HEK293T 细胞缺氧条件下 HIF-1α 的转录活性和血管内皮细胞 (ECs) 中 VEGF 诱导的 DLL4 表达[1]。
Steppogenin (0-3 μM,6 h) 在缺氧条件下抑制 HIF-1α 靶基因(VEGF、GLUT1、CXCR4 和 CA9)的 mRNA 表达[1]。
Steppogenin (0-3 μM,16 h) 抑制 HIF-1α 蛋白水平,并抑制 VEGF、CXCR4 和 CA9 的蛋白水平[1]。
Steppogenin (0-3 μM,24 h) 抑制缺氧诱导的血管 EC 增殖和迁移以及 VEGF 诱导的 EC 球体发芽[1]。
RT-PCR[1]
Cell Line: | A549 cells |
Concentration: | 0, 0.3, 1, 3 μM |
Incubation Time: | 6 h |
Result: | Suppressed the mRNA expression of HIF-1α target genes (VEGF, GLUT1, CXCR4, and CA9) under poxic conditions. |
Western Blot Analysis[1]
Cell Line: | HEK293T, A549, ARPE19 cells |
Concentration: | 0, 0.3, 1, 3 μM |
Incubation Time: | 16 h |
Result: | Significantly suppressed HIF-1α protein levels in a dose-dependent manner. reduced nuclear expression of HIF-1α under poxic conditions. Inhibited protein levels of VEGF, CXCR4, and CA9 compared with the levels detected in the vehicle control group. Suppresseed VEGF-induced DLL4 protein expression. |
Steppogenin (2 mg/kg,腹腔注射,一次) 抑制肿瘤生长和血管生成[1]。
Steppogenin (2 mg/kg,腹腔注射,一次) 在肝脏和脾脏中的分布最高 (分别为 25.5 倍和 9.74 倍 AUC 比率),T1/2 显著更高[1]。
Pharmacokinetic Parameters of Steppogenin in male C57BL/6 J mice[1].
Cmax (ng/mL) | Tmax (h) | T1/2 (h) | AUC8h (ng/mL∗h) | AUC∞ (ng/mL∗h) | AUC ratio | |
Plasma | 448 ± 113 | 0.25 | 0.49 ± 0.14 | 283 ± 98.9 | 284 ± 97.8 | 1 |
Tumor | 635 ± 114 | 0.3 ± 0.1 | 1.87 ± 0.87 | 1078 ± 494 | 1252 ± 547 | 4.58 |
Liver | 4319 ± 1063 | 0.25 | 1.72 ± 0.26 | 6733 ± 1300 | 6967 ± 1200 | 25.5 |
Lung | 521 ± 181 | 0.25 | 0.36 ± 0.12 | 261 ± 96.1 | 280 ± 106 | 1.02 |
Heart | 285 ± 15.2 | 0.25 | 0.2 | 107 ± 44.3 | 176.9 | 0.65 |
Kidney | 1225 ± 463 | 0.25 | 0.33 ± 0.01 | 628 ± 234 | 624.7 ± 238 | 2.35 |
Spleen | 6110 ± 2954 | 0.25 | 0.47 ± 0.01 | 2443 ± 1155 | 2663 ± 1289 | 9.74 |
Brain | 309 ± 95.7 | 0.25 | 1.36 ± 0.46 | 191 ± 67 | 241 ± 75.4 | 0.88 |
Animal Model: | C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)[1] |
Dosage: | 2 mg/kg |
Administration: | IP, once |
Result: | Significantly suppressed tumor growth. |
Animal Model: | C57BL/6 J mice (6-week-old, male, Lewis lung carcinoma (LLC) allograft tumor model)[1] |
Dosage: | 2 mg/kg |
Administration: | IP, once (Pharmacokinetic Analysis) |
Result: | Showed the highest distribution to the liver and spleen (25.5-fold and 9.74-fold AUC ratio, respectively) with significantly higher T1/2. may not be accumulated even in the highly distributed tissues after the repeated administration of steppogenin. |
[1]. Cha S, et al. Steppogenin suppresses tumor growth and sprouting angiogenesis through inhibition of HIF-1α in tumors and DLL4 activity in the endothelium. Ptomedicine. 2023 Jan;108:154513.
Cas No. | 56486-94-3 | SDF | Download SDF |
别名 | 草大戟素 | ||
分子式 | C15H12O6 | 分子量 | 288.25 |
溶解度 | 储存条件 | Store at -20°C | |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 3.4692 mL | 17.3461 mL | 34.6921 mL |
5 mM | 0.6938 mL | 3.4692 mL | 6.9384 mL |
10 mM | 0.3469 mL | 1.7346 mL | 3.4692 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。